Display options
Share it on

Adv Biosci Biotechnol. 2013 Aug;4(88). doi: 10.4236/abb.2013.48A2002.

Cyclophosphamide Induces an Early Wave of Acrolein-Independent Apoptosis in the Urothelium.

Advances in bioscience and biotechnology (Print)

Francis M Hughes, Alexa G Corn, Andrew R Nimmich, Jeffery D Pratt-Thomas, J Todd Purves

Affiliations

  1. Department of Urology, Medical University of South Carolina. Charleston, SC.
  2. Department of Urology, Medical University of South Carolina. Charleston, SC ; Department of Pediatrics, Medical University of South Carolina. Charleston, SC ; Department of Regenerative Medicine and Cell Biology. Medical University of South Carolina. Charleston, SC.

PMID: 24353901 PMCID: PMC3864667 DOI: 10.4236/abb.2013.48A2002

Abstract

PURPOSE: Hemorrhagic cystitis (HC or bladder inflammation) affects a significant number of patients undergoing cyclophosphamide (CP) chemotherapy despite treatment with 2-mercapto

MATERIALS AND METHODS: Apoptosis in urothelium (caspase-3/7 activity and Poly (ADP-ribosyl) polymerase (PARP) cleavage) was measured following CP administration (80 mg/kg). Sodium 2-mercaptoethane sulfonate (Mesna) was used to mask acrolein's effect. An IL-1β receptor antagonist and a cell-permeable caspase-1 inhibitor were used to assess the involvement of IL-1β and caspase-1, respectively.

RESULTS: Two waves of apoptosis were detected following CP administration, one peaking at 2 h and a second at 48 h. The first wave was independent of acrolein. Caspase-1 was also active at 2 h and activation of caspase-3/7 was blocked by a caspase-1 inhibitor but not an IL-1β receptor antagonist suggesting the direct activation of caspase-3/7 by caspase-1 without the need for IL-1β as an intermediate.

CONCLUSIONS: Our results indicate that CP initiates an early, acrolein-independent wave of apoptosis that results from direct cleavage of caspase-3/7 by caspase-1.

Keywords: Apoptosis; Bladder; Cyclophosphamide; Cystitis; Urothelium

References

  1. Nat Immunol. 2012 Mar 19;13(4):321-4 - PubMed
  2. Immunol Rev. 2011 Sep;243(1):136-51 - PubMed
  3. Exp Cell Res. 2002 Apr 1;274(2):216-25 - PubMed
  4. J Pediatr Hematol Oncol. 2011 Apr;33(3):190-3 - PubMed
  5. J Cell Biochem. 1997 Jan;64(1):50-4 - PubMed
  6. Nat Rev Nephrol. 2011 May 24;7(7):399-406 - PubMed
  7. Cancer Res. 1973 Feb;33(2):226-33 - PubMed
  8. Diabetes. 2008 May;57(5):1205-15 - PubMed
  9. Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14616-21 - PubMed
  10. Ann Pharmacother. 1995 Sep;29(9):918-21 - PubMed
  11. Int J Biochem Cell Biol. 2010 Jan;42(1):21-4 - PubMed
  12. Carcinogenesis. 1992 Dec;13(12):2281-5 - PubMed
  13. Cell Death Differ. 1999 Nov;6(11):1117-24 - PubMed
  14. J Biol Chem. 1997 Nov 28;272(48):30567-76 - PubMed
  15. Bone Marrow Transplant. 2008 Jan;41(1):11-8 - PubMed
  16. Diabetologia. 2005 Jul;48(7):1339-49 - PubMed
  17. Am J Physiol Regul Integr Comp Physiol. 2007 Jul;293(1):R125-34 - PubMed
  18. Haematologica. 2010 Jul;95(7):1183-90 - PubMed
  19. Br J Haematol. 2008 Sep;142(5):717-31 - PubMed
  20. J Neurovirol. 2003 Jun;9(3):390-8 - PubMed
  21. Clin Infect Dis. 2009 Jul 15;49(2):233-40 - PubMed
  22. Am J Physiol Renal Physiol. 2010 Mar;298(3):F589-600 - PubMed
  23. Indian J Cancer. 2006 Jan-Mar;43(1):12-5 - PubMed
  24. Arch Toxicol. 2011 Jan;85(1):51-7 - PubMed
  25. Cell Biol Int. 2003;27(10):863-9 - PubMed
  26. Biol Blood Marrow Transplant. 2011 Aug;17(8):1176-81 - PubMed
  27. Rheumatol Int. 2008 Sep;28(11):1161-4 - PubMed
  28. Urology. 2013 Jan;81(1):209.e9-14 - PubMed

Publication Types

Grant support